Vizgen vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Vizgen is a Cambridge MA life sciences company commercializing MERSCOPE, a spatial genomics platform based on MERFISH technology licensed from Harvard; enables single-cell, subcellular-resolution RNA imaging in intact tissue;
About
Vizgen is a life sciences company founded in 2019 and headquartered in Cambridge, Massachusetts, that has commercialized the MERSCOPE platform — a spatial genomics instrument based on MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology originally developed in the lab of Xiaowei Zhuang at Harvard University. MERSCOPE enables researchers to simultaneously measure the expression of hundreds to thousands of genes in individual cells while preserving the spatial location of those cells within intact tissue samples. This combination of single-cell resolution and spatial context is a significant advance over traditional bulk RNA sequencing (which loses spatial information) and earlier single-cell sequencing methods (which require tissue dissociation that destroys spatial architecture).
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.